Study of Application of Transcutaneous Trigeminal Nerve Stimulation on Autism Spectrum Disorder

NCT ID: NCT06233279

Last Updated: 2024-01-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-11-15

Study Completion Date

2024-08-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to evaluate the safety and the efficacy of applying transcutaneous trigeminal nerve stimulator (NuEyne P01) on autism spectrum disorder.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Duration of study period (per participant): Screening period (-28\~0 days), Intervention period (28 days) Patient needs to visit site at least 4 times (V1, V2, V4, V6). V2 can be done with V1. Tele-visit should be done on V3 (day 7), V5 (day 21).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autism Spectrum Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental Group

Charge-Balanced, Symmetric Nerve Stimulation device is used during night sleep for eight hours each day for 4 weeks (28 days).

Group Type EXPERIMENTAL

Charge-Balanced, Symmetric Nerve Stimulation

Intervention Type DEVICE

Charge-Balanced, Symmetric Nerve Stimulation device is used during night sleep for eight hours each day for 4 weeks (28 days).

Control Group

Sham Stimulation device is used during night sleep for eight hours each day for 4 weeks (28 days).

Group Type SHAM_COMPARATOR

Sham Stimulation

Intervention Type DEVICE

Sham Stimulation device is used during night sleep for eight hours each day for 4 weeks (28 days).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Charge-Balanced, Symmetric Nerve Stimulation

Charge-Balanced, Symmetric Nerve Stimulation device is used during night sleep for eight hours each day for 4 weeks (28 days).

Intervention Type DEVICE

Sham Stimulation

Sham Stimulation device is used during night sleep for eight hours each day for 4 weeks (28 days).

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children over 7 years old and under 12 years old
* Patients diagnosed with autism spectrum disorder
* A person who has a total intelligence index of 70 or higher and has no problems with basic language communication
* A person who agrees not to use any medical device other than this clinical trial medical device during the clinical trial period
* A person who does not take a concurrent drug from screening to the end of the study, or who can maintain the concurrent drug during the clinical trial period without any change or addition
* Voluntary written consent to participate in this clinical trial

Exclusion Criteria

* Those who participated in other clinical trials within 30 days from the screening date
* If it is difficult to understand the contents of treatment due to the limitation of intelligence index or language ability, and if it is difficult to conduct a study
* When there is a risk of clinically significant behavioral problems, emotional control problems, psychiatric symptoms, self-harm, or other harm that can affect the treatment process
* Psychiatric hospitalization history
* A person with acute or chronic medical or mental illness
* A person with a history of seizures
* Serious trauma and surgery within 1 month
* A person who is deemed to have a problem with the adhesion of electrodes due to inflammatory reactions or other dermatological problems on the skin around the forehead to which electrodes of clinical trial medical devices are attached
* If it is need to take sleep medications \[benzodiazepine, melatonin, trazodone\] (\*However, it is participated after having a washout period of at least two weeks.)
* A person who is deemed to have other reasons for prohibition of use of clinical trial medical devices (including heart-related problems, seizures, metal or electronic devices implanted in the head, people with unknown pain, pacemaker transplant, etc.)
* When it is determined by the researcher that it is difficult for the subject to continue voluntary participation in the study due to the lack of cooperation and motivation for treatment
* Other cases where it is deemed difficult to participate in the study by the researcher's judgment
Minimum Eligible Age

7 Years

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nu Eyne Co., Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hee Jeong Yoo, Ph. D., MD

Role: PRINCIPAL_INVESTIGATOR

Seoul National University Bundang Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Seoul National University Bundang Hospital

Seongnam-si, , South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jinho Jung, Ph.D candi.

Role: CONTACT

+821083113509

PyeongHwa Eun, M.S.

Role: CONTACT

+821095513095

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Hee Jeong Yoo, Ph. D., MD.

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NE_PSY_001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Therapeutic Issues for Autism
NCT03887754 COMPLETED PHASE2